

SENATE AMENDMENTS
2nd Printing

By: VanDeaver

H.B. No. 4783

A BILL TO BE ENTITLED

AN ACT

relating to a report on governmental opioid antagonist programs to reverse and prevent opioid overdoses.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. Subchapter B, Chapter 461A, Health and Safety Code, is amended by adding Section 461A.060 to read as follows:

Sec. 461A.060. BIENNIAL REPORT ON OPIOID ANTAGONIST PROGRAMS FOR OPIOID OVERDOSE REVERSAL AND PREVENTION. (a) In this section, "opioid antagonist" has the meaning assigned by Section 483.101.

(b) Not later than October 1 of each even-numbered year, the commission shall:

(1) prepare a report evaluating the distribution of opioid antagonists in this state to reverse and prevent opioid overdoses; and

(2) submit the report to the governor, the lieutenant governor, and the speaker of the house of representatives.

(c) The report described by Subsection (b) must:

(1) include a needs assessment for the opioid antagonist program established under Section 461A.059;

(2) establish a statewide saturation goal for opioid antagonists and include:

(A) a description of the data sources and methodology used to estimate insufficiencies in the current supply

1 of opioid antagonists; and

2 (B) a communications plan to address opioid
3 overdoses in areas of this state at higher risk for increased
4 numbers of overdoses;

5 (3) include a description of all state and federal
6 money appropriated to the opioid antagonist program established
7 under Section 461A.059;

8 (4) establish opioid antagonist distribution
9 strategies for this state;

10 (5) list and describe all available state and
11 federally funded purchase and distribution programs for opioid
12 antagonists; and

13 (6) recommend improvements for addressing opioid
14 overdoses among high-risk populations, including school-aged
15 children, pregnant and postpartum women, and individuals residing
16 in rural areas of this state.

17 (d) In preparing the report under this section, the
18 commission shall coordinate and consult with each state agency,
19 institution of higher education, and political subdivision of this
20 state that receives funding or other resources under Section
21 461A.059 for the distribution of opioid antagonists.

22 SECTION 2. This Act takes effect September 1, 2025.

ADOPTED

MAY 20 2025

Latey Law
Secretary of the Senate

By: *Kelly Harmon* H.B. No. 4783
Substitute the following for H.B. No. 4783:
By: *Chen* C.S. H.B. No. 4783

A BILL TO BE ENTITLED

AN ACT

relating to a report on governmental opioid antagonist programs to reverse and prevent opioid overdoses.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. Subchapter B, Chapter 461A, Health and Safety Code, is amended by adding Section 461A.060 to read as follows:

Sec. 461A.060. BIENNIAL REPORT ON OPIOID ANTAGONIST PROGRAMS FOR OPIOID OVERDOSE REVERSAL AND PREVENTION. (a) In this section, "opioid antagonist" has the meaning assigned by Section 483.101.

(b) Not later than October 1 of each even-numbered year, the commission shall:

(1) prepare a report evaluating the distribution of opioid antagonists in this state to reverse and prevent opioid overdoses; and

(2) submit the report to the governor, the lieutenant governor, and the speaker of the house of representatives.

(c) The report described by Subsection (b) must:

(1) include a needs assessment for the opioid antagonist programs established by state agencies and institutions of higher education;

(2) establish a statewide saturation goal for opioid antagonists and include:

(A) a description of the data sources and

1 methodology used to estimate insufficiencies in the current supply
2 of opioid antagonists; and

3 (B) a communications plan to address opioid
4 overdoses in areas of this state at higher risk for increased
5 numbers of overdoses;

6 (3) include a description of all state and federal
7 money appropriated to governmental opioid antagonist programs;

8 (4) establish opioid antagonist distribution
9 strategies for this state;

10 (5) list and describe all available state and
11 federally funded purchase and distribution programs for opioid
12 antagonists; and

13 (6) recommend improvements for addressing opioid
14 overdoses among high-risk populations, including school-aged
15 children, pregnant and postpartum women, and individuals residing
16 in rural areas of this state.

17 (d) In preparing the report under this section, the
18 commission shall coordinate and consult with each state agency and
19 institution of higher education that receives funding or other
20 resources for the distribution of opioid antagonists.

21 SECTION 2. This Act takes effect September 1, 2025.

LEGISLATIVE BUDGET BOARD
Austin, Texas

FISCAL NOTE, 89TH LEGISLATIVE REGULAR SESSION

May 21, 2025

TO: Honorable Dustin Burrows, Speaker of the House, House of Representatives

FROM: Jerry McGinty, Director, Legislative Budget Board

IN RE: HB4783 by VanDeaver (Relating to a report on governmental opioid antagonist programs to reverse and prevent opioid overdoses.), **As Passed 2nd House**

No significant fiscal implication to the State is anticipated.

It is assumed that any costs associated with the bill could be absorbed using existing resources.

Local Government Impact

No significant fiscal implication to units of local government is anticipated.

Source Agencies: 529 Health and Human Services Commission

LBB Staff: JMc, SD, NPe, ER, SB

LEGISLATIVE BUDGET BOARD
Austin, Texas

FISCAL NOTE, 89TH LEGISLATIVE REGULAR SESSION

May 16, 2025

TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services

FROM: Jerry McGinty, Director, Legislative Budget Board

IN RE: HB4783 by VanDeaver (Relating to a report on governmental opioid antagonist programs to reverse and prevent opioid overdoses.), **Committee Report 2nd House, Substituted**

No significant fiscal implication to the State is anticipated.

It is assumed that any costs associated with the bill could be absorbed using existing resources.

Local Government Impact

No significant fiscal implication to units of local government is anticipated.

Source Agencies: 529 Health and Human Services Commission

LBB Staff: JMc, NPe, ER, SB

LEGISLATIVE BUDGET BOARD
Austin, Texas

FISCAL NOTE, 89TH LEGISLATIVE REGULAR SESSION

May 12, 2025

TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services

FROM: Jerry McGinty, Director, Legislative Budget Board

IN RE: HB4783 by VanDeaver (Relating to a report on governmental opioid antagonist programs to reverse and prevent opioid overdoses.), **As Engrossed**

No significant fiscal implication to the State is anticipated.

It is assumed that any costs associated with the bill could be absorbed using existing resources.

Local Government Impact

No significant fiscal implication to units of local government is anticipated.

Source Agencies: 529 Health and Human Services Commission

LBB Staff: JMc, NPe, ER, SB

LEGISLATIVE BUDGET BOARD
Austin, Texas

FISCAL NOTE, 89TH LEGISLATIVE REGULAR SESSION

April 12, 2025

TO: Honorable Gary VanDeaver, Chair, House Committee on Public Health

FROM: Jerry McGinty, Director, Legislative Budget Board

IN RE: HB4783 by VanDeaver (Relating to a report on governmental opioid antagonist programs to reverse and prevent opioid overdoses.), **As Introduced**

No significant fiscal implication to the State is anticipated.

It is assumed that any costs associated with the bill could be absorbed using existing resources.

Local Government Impact

No significant fiscal implication to units of local government is anticipated.

Source Agencies: 529 Health and Human Services Commission

LBB Staff: JMc, NPe, ER, SB